Bioline RX Ltd Sponsored ADR (BLRX)
NASDAQ:BLRX
Want to see BLRX full AI Analyst Report?
Top Page
Bioline RX Ltd Sponsored ADR
(NASDAQ:BLRX)
Select Model
Select Model
Rating:51Neutral
Price Target:
$3.00
▲(22.45% Upside)
Action:Reiterated
Date:04/30/26
The score is primarily held back by weak financial performance—especially the sharp 2025 revenue drop, ongoing losses, and negative free cash flow—despite improved cash burn and a still-positive equity base. Technicals are moderately supportive with the stock trading above key shorter-term moving averages, but mixed momentum signals and limited valuation support given negative earnings keep the overall score near the middle of the range.
Positive Factors
Commercialized Product & Partnered Model
Having an approved, partner-commercialized product creates a durable non-dilutive revenue channel and validates commercial execution by a third party. Royalty/profit-share mechanics reduce direct commercialization cost and preserve focus on R&D, supporting sustained funding for pipeline progression if APHEXDA adoption grows.
Negative Factors
Severe Revenue Decline
A ~91% revenue drop signals concentrated, unstable revenue streams and loss of prior commercial activity. Such structural revenue volatility undermines predictability for R&D funding and increases dependence on financing, partnerships or milestone timing, raising execution risk for multi-year clinical programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercialized Product & Partnered Model
Having an approved, partner-commercialized product creates a durable non-dilutive revenue channel and validates commercial execution by a third party. Royalty/profit-share mechanics reduce direct commercialization cost and preserve focus on R&D, supporting sustained funding for pipeline progression if APHEXDA adoption grows.
Read all positive factors
Bioline RX Ltd Sponsored ADR (BLRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.79M
Dividend YieldN/A
Average Volume (3M)23.61K
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue Growth-95.92%
EPS Growth96.05%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.48
Shares Outstanding4,368,295
10 Day Avg. Volume24,146
30 Day Avg. Volume23,614
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.63
Price to Sales (P/S)9.57
P/FCF Ratio-1.39
Enterprise Value/Market Cap1.58
Enterprise Value/Revenue15.78
Enterprise Value/Gross Profit21.00
Enterprise Value/Ebitda-11.14
Forecast
1Y Price Target
$12.00Price Target Upside389.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.01
Revenue Forecast (FY)$1.50M
Bioline RX Ltd Sponsored ADR Business Overview & Revenue Model
Company Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phas...
How the Company Makes Money
BioLineRx generates revenue primarily from (1) product-based income tied to APHEXDA (motixafortide) via its commercial arrangement and (2) collaboration-related income such as upfront payments, milestones, and royalties from partners (when applica...
Bioline RX Ltd Sponsored ADR Earnings Call Summary
Earnings Call Date:Nov 24, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:May 27, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mix of positive developments in R&D ventures and strong financial management, offset by minimal revenue growth and reduced operational expenses. The company's strategic focus on innovative treatments and a solid cash position are promising, but current revenue generation and market penetration remain challenges.Positive Updates
Joint Venture with Hemispherian
BioLineRx established a JV with Hemispherian to develop GLIX1 for glioblastoma and other cancers, combining expertise in cancer drug discovery and regulatory success.
Negative Updates
Minimal Revenue Generation
Q3 2025 revenues were only $0.4 million, reflecting royalties from APHEXDA sales, indicating slow market penetration.
Read all updates
Q3-2025 Updates
Positive
Negative
Joint Venture with Hemispherian
BioLineRx established a JV with Hemispherian to develop GLIX1 for glioblastoma and other cancers, combining expertise in cancer drug discovery and regulatory success.
Read all positive updates
Company Guidance
During the BioLineRx Third Quarter 2025 Financial Results Conference Call, significant guidance was provided regarding the future direction and strategic initiatives of the company. A key highlight was the establishment of a joint venture (JV) with Hemispherian to develop GLIX1, a first-in-class oral molecule targeting glioblastoma with an FDA-cleared IND, aiming to initiate a Phase I/IIa trial in early 2026. The JV agreement grants Hemispherian a 60% stake, while BioLineRx holds 40%, with plans to increase its stake to 70% as it invests further. The company reported Q3 revenues of $0.4 million from APHEXDA royalties and a net loss of $1 million, with cash reserves of $25.2 million expected to support operations into the first half of 2027. BioLineRx is optimistic about GLIX1's potential across various cancer indications, supported by a robust patent portfolio extending through at least 2040.Bioline RX Ltd Sponsored ADR Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
43
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.19M | 28.94M | 4.80M | 0.00 | 0.00 |
| Gross Profit | 430.39K | 19.68M | 1.11M | 0.00 | 0.00 |
| EBITDA | -9.84M | 3.92M | -57.09M | -28.50M | -24.07M |
| Net Income | -1.18M | -9.22M | -60.61M | -24.95M | -27.05M |
Balance Sheet | |||||
| Total Assets | 40.90M | 38.91M | 63.92M | 76.38M | 81.39M |
| Cash, Cash Equivalents and Short-Term Investments | 20.88M | 19.56M | 42.99M | 51.08M | 57.13M |
| Total Debt | 10.15M | 15.04M | 11.59M | 12.32M | 4.65M |
| Total Liabilities | 17.56M | 25.45M | 50.70M | 25.54M | 13.30M |
| Stockholders Equity | 18.20M | 13.46M | 13.22M | 50.84M | 68.09M |
Cash Flow | |||||
| Free Cash Flow | -8.16M | -43.93M | -22.91M | -26.56M | -23.67M |
| Operating Cash Flow | -8.14M | -43.87M | -22.61M | -26.24M | -23.57M |
| Investing Cash Flow | -8.61M | 29.37M | 1.44M | 4.01M | -38.22M |
| Financing Cash Flow | 8.95M | 20.66M | 15.06M | 20.44M | 57.75M |
Bioline RX Ltd Sponsored ADR Technical Analysis
Positive
2.45
Price Trends
2.60
Positive
2.74
Positive
3.16
Negative
Market Momentum
0.09
Positive
57.64
Neutral
48.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLRX, the sentiment is Positive. The current price of 2.45 is below the 20-day moving average (MA) of 2.93, below the 50-day MA of 2.60, and below the 200-day MA of 3.16, indicating a neutral trend. The MACD of 0.09 indicates Positive momentum. The RSI at 57.64 is Neutral, neither overbought nor oversold. The STOCH value of 48.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BLRX.
Bioline RX Ltd Sponsored ADR Risk Analysis
Bioline RX Ltd Sponsored ADR disclosed 43 risk factors in its most recent earnings report. Bioline RX Ltd Sponsored ADR reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bioline RX Ltd Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $14.54M | -1.77 | -89.92% | ― | ― | 63.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $11.79M | -2.16 | -22.03% | ― | -95.92% | 96.05% | |
49 Neutral | $7.72M | 2.78 | -27.54% | ― | ― | -138.25% | |
49 Neutral | $12.75M | -1.84 | ― | ― | ― | 80.65% | |
46 Neutral | $19.25M | -0.24 | -67.42% | ― | ― | 55.15% | |
42 Neutral | $16.76M | -0.83 | -135.04% | ― | ― | 42.29% |
* Healthcare Sector Average
BLRX
Bioline RX Ltd Sponsored ADR
3.06
-0.60
-16.39%
SYBX
Synlogic
0.66
-0.47
-41.59%
MBRX
Moleculin Biotech
2.39
-21.38
-89.95%
CTXR
Citius Pharmaceuticals
0.70
>-0.01
-0.28%
CMMB
Chemomab Therapeutics
2.02
-3.58
-63.93%
PASG
Passage Bio
5.23
-1.94
-27.03%
Bioline RX Ltd Sponsored ADR Corporate Events
BioLineRx and Hemispherian Showcase New GLIX1 Data Ahead of ASCO 2026 as First-in-Human GBM Trial Enrolls
May 22, 2026
On May 22, 2026, BioLineRx and Hemispherian announced that two abstracts on their lead candidate GLIX1 will be featured at the ASCO 2026 Annual Meeting in Chicago, underscoring rising scientific interest in this first-in-class TET2-activating smal...
BioLineRx and Hemispherian Report Strong Preclinical GLIX1 Data in Temozolomide-Resistant Glioblastoma
May 19, 2026
On May 19, 2026, BioLineRx and Hemispherian reported new preclinical data for GLIX1, an orally administered, brain-penetrating TET2 pathway activator, showing robust anti-tumor activity in multiple glioblastoma models. The drug produced significan...
BioLineRx and Hemispherian Dose First Patient in Phase 1/2a GLIX1 Glioblastoma Trial
Apr 28, 2026
BioLineRx Ltd., a clinical-stage biopharmaceutical company specializing in oncology and rare diseases, is advancing GLIX1 as its lead asset, targeting DNA damage response in glioblastoma and other solid tumors, alongside its approved stem cell mob...
BioLineRx Launches First-in-Human Trial of GLIX1 for Glioblastoma
Mar 26, 2026
BioLineRx Ltd., a clinical-stage biopharmaceutical company specializing in oncology and rare diseases, is advancing a pipeline led by GLIX1, a first-in-class DNA damage response modulator for glioblastoma and other solid tumors, alongside its appr...
BioLineRx Sets March Start for GLIX1 Brain Cancer Trial as 2025 Results Show Leaner R&D-Focused Model
Mar 23, 2026
On March 23, 2026, BioLineRx reported audited 2025 results and said it remains on track to launch a Phase 1/2a first-in-human trial of GLIX1 in glioblastoma by the end of March, with three leading U.S. cancer centers participating. The study will ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.